HRP920667B1 - Application of fultripine active substance for preventing muscle deformation - Google Patents

Application of fultripine active substance for preventing muscle deformation

Info

Publication number
HRP920667B1
HRP920667B1 HRP-1227/91A HRP920667A HRP920667B1 HR P920667 B1 HRP920667 B1 HR P920667B1 HR P920667 A HRP920667 A HR P920667A HR P920667 B1 HRP920667 B1 HR P920667B1
Authority
HR
Croatia
Prior art keywords
fultripine
application
active substance
preventing muscle
muscle deformation
Prior art date
Application number
HRP-1227/91A
Other languages
English (en)
Inventor
Peter Emig
Original Assignee
Peter Emig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from YU122791A external-priority patent/YU48054B/sh
Application filed by Peter Emig filed Critical Peter Emig
Publication of HRP920667A2 publication Critical patent/HRP920667A2/xx
Publication of HRP920667B1 publication Critical patent/HRP920667B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP-1227/91A 1990-07-14 1992-09-30 Application of fultripine active substance for preventing muscle deformation HRP920667B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (fr) 1990-07-14 1991-06-04
YU122791A YU48054B (sh) 1990-07-14 1991-07-12 Postupak za proizvodnju farmaceutskog preparata

Publications (2)

Publication Number Publication Date
HRP920667A2 HRP920667A2 (en) 1996-10-31
HRP920667B1 true HRP920667B1 (en) 1998-06-30

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP-1227/91A HRP920667B1 (en) 1990-07-14 1992-09-30 Application of fultripine active substance for preventing muscle deformation

Country Status (30)

Country Link
US (2) US5162346A (fr)
EP (2) EP0467164B1 (fr)
KR (1) KR0182811B1 (fr)
CN (1) CN1070700C (fr)
AT (2) ATE206919T1 (fr)
AU (1) AU634073B2 (fr)
CA (1) CA2046943C (fr)
CZ (1) CZ280879B6 (fr)
DE (3) DE59109222D1 (fr)
DK (2) DK0659410T3 (fr)
EG (1) EG19814A (fr)
ES (2) ES2082887T3 (fr)
GR (1) GR3019179T3 (fr)
HR (1) HRP920667B1 (fr)
HU (1) HU206973B (fr)
IE (1) IE74688B1 (fr)
IL (1) IL98810A (fr)
IN (1) IN172468B (fr)
LT (1) LT3593B (fr)
LV (1) LV10048B (fr)
MC (1) MC2272A1 (fr)
MX (1) MX9100160A (fr)
NO (1) NO912758L (fr)
NZ (1) NZ238940A (fr)
PT (1) PT98291B (fr)
RO (1) RO108220B1 (fr)
RU (1) RU2070408C1 (fr)
SI (1) SI9111227B (fr)
SK (1) SK279567B6 (fr)
ZA (1) ZA915466B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CZ2002411A3 (cs) * 1999-08-03 2003-03-12 Awd. Pharma Gmbh & Co. Kg Farmaceutický prostředek pro léčení bolesti stejně jako prevenci chronických bolestí při degenerativních chorobách kloubů u psů a koček
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
WO2005072705A1 (fr) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combinaison d'antagoniste de recepteur nmda et d'inhibiteur mao ou gadpf pour le traitement d'affections liees au systeme nerveux central
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (fr) * 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20090318507A2 (en) * 2006-05-02 2009-12-24 Chris Rundfeldt Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PT2061465E (pt) * 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EA201070189A1 (ru) * 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
ATE46265T1 (de) * 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
EP0193056B1 (fr) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Combinaison de la flupirtine avec des spasmolytiques à effet anticholinergique
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
HUT59313A (en) 1992-05-28
NO912758D0 (no) 1991-07-12
DK0467164T3 (da) 1996-03-04
MX9100160A (es) 1992-02-28
PT98291A (pt) 1992-05-29
EP0467164A3 (en) 1992-04-15
CA2046943A1 (fr) 1992-01-15
ES2082887T3 (es) 1996-04-01
PT98291B (pt) 1999-01-29
ATE133564T1 (de) 1996-02-15
IE74688B1 (en) 1997-07-30
LTIP919A (en) 1995-03-27
US5284861A (en) 1994-02-08
DK0659410T3 (da) 2001-12-27
DE59107331D1 (de) 1996-03-14
EP0467164A2 (fr) 1992-01-22
LV10048A (lv) 1994-05-10
EP0659410B1 (fr) 2001-10-17
CZ280879B6 (cs) 1996-04-17
AU634073B2 (en) 1993-02-11
SI9111227A (en) 1995-06-30
ZA915466B (en) 1992-04-29
MC2272A1 (fr) 1993-06-23
SK279567B6 (sk) 1999-01-11
RU2070408C1 (ru) 1996-12-20
EP0659410A3 (fr) 1995-10-25
KR920002147A (ko) 1992-02-28
IL98810A0 (en) 1992-07-15
LT3593B (en) 1995-12-27
LV10048B (en) 1995-06-20
HU206973B (en) 1993-03-01
CA2046943C (fr) 1996-03-12
IN172468B (fr) 1993-08-14
ES2164111T3 (es) 2002-02-16
CS210191A3 (en) 1992-02-19
KR0182811B1 (ko) 1999-05-01
RO108220B1 (ro) 1994-03-31
GR3019179T3 (en) 1996-06-30
CN1070700C (zh) 2001-09-12
IL98810A (en) 1996-01-19
EG19814A (en) 1996-02-29
IE912451A1 (en) 1992-01-15
HRP920667A2 (en) 1996-10-31
EP0467164B1 (fr) 1996-01-31
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
CN1058716A (zh) 1992-02-19
HU912359D0 (en) 1991-12-30
SI9111227B (sl) 2000-12-31
ATE206919T1 (de) 2001-11-15
NO912758L (no) 1992-01-15
DE59109222D1 (de) 2001-11-22
AU8040391A (en) 1992-01-16
EP0659410A2 (fr) 1995-06-28
DE4122166A1 (de) 1992-01-16

Similar Documents

Publication Publication Date Title
HRP920667A2 (en) Application of fultripine active substance for preventing muscle deformation
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
AU1687592A (en) 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
HU9502585D0 (en) Use of riluzole for treating aids-related neural disorders
AU8656491A (en) 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
PH27352A (en) 4-Benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
DE59104412D1 (de) Dynamische Redressionsschiene zur Therapie der Vorfussadduktion.
SE8703308D0 (sv) Therapeutic agent for the treatment of disorders associated with cerebral ischemia
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
NO950842L (no) Diarylpiperazinoacetamidforbindelser som antimuskariniske midler
RU93035807A (ru) Способ лечения юношеского эпифизиолиса
AU4533693A (en) N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds for treatment of circulatory disorders
IL106917A0 (en) Compositions for the treatment of skin disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: AWD. PHARMA GMBH & CO. KG, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20100702

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20110713